Cetuximab

• 

  Subject Areas on Research

  • A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. 
  • Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). 
  • Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. 
  • Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. 
  • Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. 
  • Cell signaling modifiers in prostate cancer. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. 
  • Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. 
  • Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. 
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. 
  • Colon cancer, version 3.2014. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
  • Epidermal growth factor receptor-targeted therapy for pancreatic cancer. 
  • Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. 
  • Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. 
  • Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. 
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • Targeted therapies for cancer 2004. 
  • Targeted therapy in rectal cancer. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. 
  • X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.